Personalized Cancer Therapy: YES1 Is the New Kid on the Block
- PMID: 31772072
- DOI: 10.1158/0008-5472.CAN-19-2995
Personalized Cancer Therapy: YES1 Is the New Kid on the Block
Abstract
The key bottleneck for the continued success of precision medicine in cancer lies in identifying more targetable genes and associated efficacious clinically usable inhibitors. In this issue of Cancer Research, Hamanaka and colleagues identify YES1 kinase as a targetable cancer target and generate an effective chemical inhibitor for YES1 and demonstrate its efficacy in YES1-amplified tumors.See related article by Hamanaka et al., p. 5734.
©2019 American Association for Cancer Research.
Comment in
-
YES1 Is a Targetable Oncogene in Cancers Harboring YES1 Gene Amplification.Cancer Res. 2019 Nov 15;79(22):5734-5745. doi: 10.1158/0008-5472.CAN-18-3376. Epub 2019 Aug 7. Cancer Res. 2019. PMID: 31391186
Comment on
-
YES1 Is a Targetable Oncogene in Cancers Harboring YES1 Gene Amplification.Cancer Res. 2019 Nov 15;79(22):5734-5745. doi: 10.1158/0008-5472.CAN-18-3376. Epub 2019 Aug 7. Cancer Res. 2019. PMID: 31391186
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
